We advised WSE-listed Pure Biologics S.A. on a PLN 12 million financing transaction

We advised WSE-listed Pure Biologics S.A. in a transaction to raise PLN 12 million in financing from a new investor, ACRX Investments Ltd.

The transaction was executed on the basis of an investment agreement and a loan agreement. The structure of the transaction envisaged that the Investor provided the Company with debt financing convertible into new issue shares of the Company and that the Company issued subscription warrants to the Investor.

Our advisory services were comprehensive and included the preparation and negotiation of transaction documentation, advice on the implementation of disclosure obligations, as well as the preparation of draft resolutions of the Company’s general meeting.

Pure Biologics is a biopharmaceutical company operating on the market since 2010. The Company’s activities focus on the discovery and development of biological drugs and the development of extracorporeal therapies. It operates in the areas of immuno-oncology, autoimmunity and neurological rare diseases, conducting research using proprietary technology platforms to select active molecules – antibodies and aptamers.

ACRX is a European transactional and distribution company in the TV rights market and is an investor in areas such as new technologies, web applications and biotechnology. ACRX is a major shareholder in one of the leading producers and publishers of computer games listed on the WSE.